Abstract:Background The persistence of hepatitis C virus (HCV) infection remains as a major cause of liver cirrhosis and hepatocellular carcinoma. HCV infection is often asymptomatic, thus diagnosis relies heavily on clinical laboratory assays. As an indirect test, the anti-HCV screening assay fails to detect HCV infection in the seroconversion window and might report false-negative results in severely immunosuppressed populations.However, it is cheaper, simpler, and can provide results more rapidly. Therefore it remains the preferred method for screening HCV infection in most clinical laboratories.As a newly developed anti-HCV screening assay, the Elecsys anti-HCV Ⅱ assay has been recently launched. Objective To evaluate Elesys anti-HCV Ⅱ assay performance in Chinese populations and compare it with other widely used anti-HCV screening methods. Methods Four HCV seroconversion panels, 861 fresh consecutive serum samples under routine clinical conditions, 100 preselected serum samples with low positive anti-HCV results (tested before using the Vitros anti-HCV assay) and 178 samples from patients with HIV infection were tested the Elecsys anti-HCV Ⅱ assay and two comparator assays, Architect anti-HCV and Vitros anti-HCV assay. Confirmatory test was performed using recombinant immunoblot assay (RIBA) 3.0 or HCV RNA tests. Moreover, 203 samples with different HCV genotypes were assessed using the Elecsys anti-HCV Ⅱ assay to test its genotype inclusivity. Results The Elecsys anti-HCV Ⅱ assay detected HCV seroconversion 7-14 days earlier than the Architect anti-HCV and Vitros anti-HCV assay. It had 100% sensitivity and superior specificity in screening clinical routine samples. For the routine samples with positive anti-HCV by all the three screening assays, the S/Co values obtained using Elecsys anti-HCV Ⅱ did not correlate with those obtained Architect anti-HCV (P=0.13) Vitros anti-HCV (P=0.22) the S/Co values obtained correlated very well with a Pearson correlation coefficient of 0.97(P<0.01). Totally 73 preselected samples with low positive anti-HCV results remained anti-HCV positive when retested the Vitros anti-HCV assay, among which only 18 samples tested positive using Elecsys anti-HCV Ⅱ and 36 samples tested positive using the Architect anti-HCV assay. The Elecsys anti-HCV Ⅱ assay significantly distinguished the 73 anti-HCV borderline results; 55 negative samples tested using Elecsys anti-HCV Ⅱ had S/Co ratios 0.038-0.13, while 18 positive samples had S/Co ratios 13.58-135.6, respectively.Only one sample with an S/Co ratio of 13.58 by Elecsys anti-HCV Ⅱ was confirmed as RIBA indeterminate, while the other 17 samples with S/Co ≥20.0 were all RIBA positive. There were 161 out of 178 samples from HIV infected patients tested anti-HCV positive while 14 samples tested negative using all the three screening.The remaining three samples generated discordant results among the anti-HCV screening assays. The Elecsys anti-HCV Ⅱ assay, the Architect anti-HCV and the Vitros anti-HCV assay detected 97.6% (122/125) anti-HCV-positive samples from HIV-infected patients with HCV viremia. Using the Elecsys anti-HCV Ⅱ assay, however, the anti-HCV levels in the genotype 3b samples were slightly underestimated. Conclusions The Elecsys anti-HCV Ⅱ can further shorten the HCV seroconversion window due to its superior sensitivity. It is sensitive and specific enough for screening HCV infection in clinical routine samples as well.The Elecsys anti-HCV Ⅱ assay can be used together with either the Architect anti-HCV or the Vitros anti-HCV assay to improve the specificity in detecting samples with borderline positive anti-HCV S/Co ratios; this strategy will avoid unnecessary medical visits and psychological harm patients with a borderline positive anti-HCV result. The Elecsys anti-HCV Ⅱ assay is also suitable for testing samples from the immunocompromised patients, due to satisfactory sensitivity. Nevertheless, further investigation of its subtype inclusivity in a larger sample number might be warranted. Key words: Hepatitis C virus; Hepatitis C Anti bodies; Genotype

Comparison of diagnostic performance among Abbott RealTime HCV Genotyping II, Abbott HCV Genotype plus RUO, and Roche Cobas HCV Genotyping assays for hepatitis C virus genotyping

Performance Comparison of the Versant Hcv Genotype 2.0 Assay (lipa) and the Abbott Realtime Hcv Genotype Ii Assay for Detecting Hepatitis C Virus Genotype 6

Comparison of a dual antibody and antigen HCV immunoassay to standard of care algorithmic testing

Profile of the VERSANT HCV Genotype 2.0 Assay.

Hepatitis Gene Chip in Detecting HBV DNA, HCV RNA in Serum and Liver Tissue Samples of Hepatitis Patients.

Hepatitis C Virus Genotype Analysis In Chronic Hepatitis Patients And Individuals With Spontaneous Virus Clearance Using A Newly Developed Serotyping Assay

A Newly Developed Hepatitis C Virus Screening Assay, Elecsys Anti-Hcv Ⅱ Assay: Performance Evaluation and Comparison with Other Widely Used Assays

Comparison of the results for three automated immunoassay systems in determining serum HBV markers.

Comparison of Gene Chip and Line Probe Assays for Hepatitis C Virus Genotyping

Comparison of a hepatitis C core antigen assay to nucleic acid amplification testing for detection of hepatitis C viremia in a US population

Performance Evaluation and Comparison of the Newly Developed Elecsys Anti-Hcv II Assay with Other Widely Used Assays

A multi-center performance evaluation of different hepatitis C virus core antigen assays for clinical infection screening

New hepatitis C virus (HCV) genotyping system that allows for identification of HCV genotypes 1a, 1b, 2a, 2b, 3a, 3b, 4, 5a, and 6a

Clinical diagnostic performance of light-initiated chemiluminescent assay compared with the Architect chemiluminescence immunoassay for detection of HCV antibody.

Improving HCV diagnosis following a false-negative anti-HCV result

Performance of HCV core antigen and PCR testing in a predominantly genotype 3 population

Comparison of two HBV DNA detection kits

Performance characteristics of the EIAgen hepatitis C virus antibody kit assay

Technical Validation of a Hepatitis C Virus Whole Genome Sequencing Assay for Detection of Genotype and Antiviral Resistance in the Clinical Pathway

Clinical utility of hepatitis C virus core antigen assay in the monitoring of direct-acting antivirals for chronic hepatitis C

Performance evaluation of the mindray anti-HCV assay for the detection of hepatitis C virus infection.